European Journal of Cancer
Volume 46, Issue 13 , Pages 2399-2407 , September 2010

Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma

  • Nadège Gruel

      Affiliations

    • Institut Curie, Translational Research Department, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • Institut Curie, INSERM Unit 830, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Carlo Lucchesi

      Affiliations

    • Institut Curie, INSERM Unit 830, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Virginie Raynal

      Affiliations

    • Institut Curie, INSERM Unit 830, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Manuel J. Rodrigues

      Affiliations

    • Institut Curie, INSERM Unit 830, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Gaëlle Pierron

      Affiliations

    • Institut Curie, Unité de Génétique Somatique, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Rémi Goudefroye

      Affiliations

    • Institut Curie, Department of Tumour Biology, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Paul Cottu

      Affiliations

    • Institut Curie, Department of Medical Oncology, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Fabien Reyal

      Affiliations

    • Institut Curie, Department of Surgery, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Xavier Sastre-Garau

      Affiliations

    • Institut Curie, Department of Tumour Biology, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Alain Fourquet

      Affiliations

    • Institut Curie, Department of Radiation Therapy, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Olivier Delattre

      Affiliations

    • Institut Curie, INSERM Unit 830, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • ,
  • Anne Vincent-Salomon

      Affiliations

    • Institut Curie, INSERM Unit 830, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • Institut Curie, Department of Tumour Biology, 26 rue d’Ulm, 75248 Paris cédex 05, France
    • Corresponding Author InformationCorresponding author at: Institut Curie, Department of Tumour Biology, 26 rue d’Ulm, 75248 Paris cédex 05, France. Tel.: +33 1 44 32 42 15; fax: +33 1 53 10 40 10.

Received 29 January 2010 ,Revised 1 April 2010 ,Accepted 7 May 2010.

References 

  1. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149–R156
  2. Sastre-Garau X, Jouve M, Asselain B, et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996;77:113–120
  3. Viale G, Rotmensz N, Maisonneuve P, et al. Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat. 2009;117(1):211–214
  4. Ferlicot S, Vincent-Salomon A, Medioni J, et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer. 2004;40(3):336–341
  5. du Toit RS, Locker AP, Ellis IO, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol. 1991;17:251–257
  6. Horn PL, Thompson WD. Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors. Cancer. 1988;62:412–424
  7. Peiro G, Bornstein B, Connolly J, et al. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat. 2000;59:49–54
  8. Bollet MA, Savignoni A, Pierga JY, et al. High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies. Br J Cancer. 2008;98(4):734–741
  9. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23(1):41–48doi:10.1200/JCO.2005.03.111
  10. Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004;40(3):342–351
  11. Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17(8):1228–1233doi:10.1093/annonc/mdl114
  12. Vos CB, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997;76(9):1131–1133
  13. Günther K, Merkelbach-Bruse S, Amo-Takyi BK, et al. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol. 2001;193:40–47
  14. Reis-Filho JS, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006;12(22):6652–6662
  15. Hoff E, Tubbs R, Myles J, Procop G. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 2002;117:916–921
  16. Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997;57(19):4360–4367
  17. Oyama T, Kashiwabara K, Yoshimoto K, Arnold A, Koerner F. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 1998;58:2876–2880
  18. Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31(3):417–426
  19. Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O. ESR1 gene amplification in breast cancer: a common phenomenon?. Nat Genet. 2008;40(7):809;[author reply 810–2]
  20. Vincent-Salomon A, Lucchesi C, Gruel N, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008;14(7):1956–1965
  21. Nishizaki T, Chew K, Chu L, et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer. 1997;74:513–517
  22. Loo LWM, Grove DI, Williams EM, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res. 2004;64(23):8541–8549
  23. Bernard-Pierrot I, Gruel N, Stransky N, et al. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res. 2008;68(17):7165–7175
  24. Roy PG, Pratt N, Purdie CA, et al. Int J Cancer. 2009;
  25. Zhang Q, Gu J, Li L, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009;16(5):413–424
  26. Bertucci F, Orsetti B, Negre V, et al. Oncogene. 2008;
  27. Korkola JE, DeVries S, Fridlyand J, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 2003;63(21):7167–7175
  28. Turashvili G, Bouchal J, Baumforth K, et al. BMC Cancer. 2007;7:55
  29. Weigelt B, Geyer FC, Natrajan R, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol. 2010;220(1):45–57

PII: S0959-8049(10)00385-0

doi: 10.1016/j.ejca.2010.05.013

European Journal of Cancer
Volume 46, Issue 13 , Pages 2399-2407 , September 2010

Article Tools

* Image Usage & Resolution